SAILOR Cohort 1 Results
Dr. Boyer discusses the SAILOR cohort 1 results which evaluated safety, efficacy, and tolerability of intravitreal treatment of ranibizumab (trade name Lucentis) in patients with wet AMD.
2,428 video views and 12,740 series views since 5/13/2008
Comments (0)